Related Experiment Video
Updated: Aug 21, 2026

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
Published on: April 21, 2014
Characterisation of recombinant HERG K+ channel blockade by the Class Ia antiarrhythmic drug procainamide
John M Ridley1, James T Milnes, Andrew V Benest
1Department of Physiology and Cardiovascular Research Laboratories, School of Medical Sciences, University Walk, BS8 1TD, Bristol, UK
Insights
Procainamide (PROC) inhibits the HERG K(+) channel, a key factor in drug-induced arrhythmias. Its blocking potency is lower than other Class Ia drugs, suggesting structural differences influence HERG channel interactions.
Area of Science:
- Cardiovascular pharmacology
- Molecular electrophysiology
- Ion channel research
Background:
- Class Ia antiarrhythmic drugs, like procainamide (PROC), can cause pro-arrhythmia by affecting cardiac ion channels.
- The HERG K(+) channel is implicated in drug-induced pro-arrhythmia.
Purpose of the Study:
- To investigate the interaction between procainamide (PROC) and HERG K(+) channels.
- To determine the potency and mechanism of PROC's action on HERG channels.
Main Methods:
- Whole-cell patch-clamp recordings of HERG current (I(HERG)) in HEK 293 cells expressing HERG channels.
- Application of activating pulses and varying membrane potentials to assess PROC's inhibitory effects.
Main Results:
- PROC inhibited I(HERG) with an IC(50) of approximately 139 microM.
- Blockade was time- and voltage-dependent, indicating interaction with open/activated HERG channel states.
- Inhibition was reduced at highly positive potentials favoring HERG channel inactivation.
Conclusions:
- PROC inhibits HERG K(+) channels primarily through an open/activated state block.
- Reduced drug-binding avidity correlates with HERG channel inactivation.
- PROC's lower potency compared to quinidine/disopyramide highlights structural determinants of HERG channel blockade.
Abstract:
Class Ia antiarrhythmic drugs, including procainamide (PROC), are associated with cardiac sodium channel blockade, delayed ventricular repolarisation and with a risk of ventricular pro-arrhythmia. The HERG K(+) channel is frequently linked to drug-induced pro-arrhythmia. Therefore, in this study, interactions between PROC and HERG K(+) channels were investigated, with particular reference to potency and mechanism of drug action. Whole-cell patch-clamp recordings of HERG current (I(HERG)) were made at 37 degrees C from human embryonic kidney (HEK 293) cells stably expressing the HERG channel. Following activating pulses to +20 mV, I(HERG) tails were inhibited by PROC with an IC(50) value of approximately 139 microM. I(HERG) blockade was found to be both time- and voltage-dependent, demonstrating contingency upon HERG channel gating. However, I(HERG) inhibition by PROC was relieved by depolarisation to a highly positive membrane potential (+80 mV) that favoured HERG channel inactivation. These data suggest that PROC inhibits the HERG K(+) channel by a primarily 'open' or 'activated' channel state blocking mechanism and that avidity of drug-binding is decreased by extensive I(HERG) inactivation. The potency of I(HERG) blockade by PROC is much lower than for other Class Ia agents that have been studied previously under analogous conditions (quinidine and disopyramide), although the blocking mechanism appears similar. Thus, differences between the chemical structure of PROC and other Class Ia antiarrhythmic drugs may help provide insight into chemical determinants of blocking potency for agents that bind to open/activated HERG channels.
More Related Videos
14:03High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Published on: March 24, 2023
08:11Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
Published on: November 11, 2022
Related Concept Videos
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inotropic Agents
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...